Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bio-Path Holdings
(NQ:
BPTH
)
1.498
+0.008 (+0.50%)
Streaming Delayed Price
Updated: 12:49 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bio-Path Holdings
< Previous
1
2
Next >
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
August 15, 2024
Conference Call to be Held Today at 8:30 A.M. ET
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
August 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Provides Clinical Update and Expansion Plans
July 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
June 14, 2024
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 05, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
June 04, 2024
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate...
Via
Newsfile
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 04, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2024
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
May 24, 2024
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Reports First Quarter 2024 Financial Results
May 15, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
May 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 19, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 18, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Inc. (NASDAQ: BPTH) Near Top of Volume Charts in Thursday Trading
April 18, 2024
Via
Investor Brand Network
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
April 18, 2024
BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 Protein
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Expands Global Patent Portfolio
April 15, 2024
Builds on Global Intellectual Property Portfolio to Protect DNAbilize® Platform
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Provides 2024 Clinical and Operational Update
April 02, 2024
Clinical Advances Across Multiple Programs with Several Milestones
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
March 27, 2024
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate...
Via
Newsfile
Bio-Path Holdings Reports Full Year 2023 Financial Results
March 08, 2024
Conference Call to be Held Today at 8:30 A.M. ET
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
March 01, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
February 21, 2024
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
January 10, 2024
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
December 14, 2023
BP1002 Offers Unique Opportunity for Venetoclax-Resistant Patients by Utilizing RNAi to Limit Cells’ Ability to Produce Bcl-2 Protein
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
November 15, 2023
Conference Call to be Held Today at 8:30 A.M. ET
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
November 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
October 24, 2023
Conference call to be held on Monday, October 30, 2023 at 9:00 a.m. ET
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.